Health and Healthcare
IPO Filing Floodgates: Aegerion Pharmaceuticals, Inc. (AEGR)
Published:
Last Updated:
Aegerion Pharmaceuticals, Inc. filed Tuesday for an initial public offering of up to $86.25 million in securities for filing purposes. It has the proposed ticker of "AEGR" on NASDAQ, and the underwriting group consists of Piper Jaffray, Thomas Weisel partners, Lazard Capital Markets, and Collins Stewart, LLC.
Aegerion is an emerging biotech company focused on small-molecule therapeutics to treat cardiovascular and metabolic disease. Its lead product candidates, AEGR-733 and AEGR-427, are microsomal triglyceride transfer protein inhibitors, or MTP-Is, which limit secretion of cholesterol and triglycerides from both the intestine and liver.
24/7 Wall St. will have to do some research here because this IPO had originally been filed back in March 2007, but was withdrawn from registration in June.
If you wish to join our open email distribution list we often provide more detailed IPO and spin-off coverage. These are frequently lead-ins to our subscriber-based "Special Situation Investing Newsletter" where we cover buyouts, spin-offs, back-door plays into IPO’s, reorganizations, and more.
Jon C. Ogg
November 21, 2007
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.